BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026
BridgeBio and its partner Bayer announced upcoming presentations of new data from the Phase 3 ATTRibute-CM study of acoramidis at the ESC-HF 2026 conference in Barcelona. The featured data includes a late-breaking oral presentation on the drug's impact on outpatient worsening heart failure, alongside additional analyses of biomarkers, hospitalization risk, and patient-reported health status. Acoramidis is currently approved as Attruby in the U.S.
Key figures
- Drug Name
- acoramidis (Attruby)
- Phase Of Trial
- Phase 3
- Diarrhea attruby
- 11.6%
- Diarrhea placebo
- 7.6%
- Abdominal pain attruby
- 5.5%
- Abdominal pain placebo
- 1.4%
- Discontinuation attruby
- 9.3%
- Discontinuation placebo
- 8.5%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.